Social, policy, and public health perspectives on new psychoactive substances

Drug Testing and Analysis

Volumn 3, Issue 7-8, 2011, Pages 515-523

  Sumnall, H R ^a   Evans Brown, M ^a   Mcveigh, J ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Drug policy; Entactogens; Hallucinogens; Legal highs; New psychoactives

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; RISK ASSESSMENT; TARGETED DRUG DELIVERY;

DRUG POLICY; ENTACTOGEN; HALLUCINOGEN; HEALTH PERSPECTIVE; HEALTH RESPONSE; LEGAL HIGH; MONITORING SYSTEM; NEW PSYCHOACTIVE; SOCIAL POLICY; USERS PERSPECTIVE;

PUBLIC HEALTH;

1 BENZYLPIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPYROVALERONE; 4 METHYLTHIOAMPHETAMINE; 4' METHYLMETHCATHINONE; 6 (2 AMINOPROPYL)BENZOFURAN; AMPHETAMINE DERIVATIVE; ILLICIT DRUG; LYSERGIDE; METHEDRONE; METHYLONE; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; TRAZODONE; UNCLASSIFIED DRUG;

CHINA; CRIMINAL JUSTICE; CULTURAL FACTOR; DEREGULATION; DRUG BIOAVAILABILITY; DRUG CONTROL; DRUG COST; DRUG FORMULATION; DRUG INTOXICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; FORENSIC TOXICOLOGY; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; INTERNET; MEDICAL LITERATURE; NEUROTOXICITY; NONHUMAN; POLITICS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SELF REPORT; SEROTONINERGIC SYSTEM; SUBSTANCE ABUSE;

EID: 79960629349     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.310     Document Type: Review

References (129)

1. S. Blackman, in Drugs in Britain: Supply, Consumption and Control. (Eds: M. Simpson, T. Shildrick, R. MacDonald ), Palgrave Macmillan: Hampshire, 2007, pp. 39-59.
2. M. A. Lee, B. ShlaAcid Dreams, Grove Press: New York, 1992.
3. R. DeGrandpre. The Cult of Pharmacology: How America Became the World's Most Troubled Drug Culture, Duke University Press: Durham, 2006.
4. N. Rasmussen. On Speed. The Many Lives of Amphetamine, New York University Press: New York, 2008.
5. L. Dyck. Psychedelic Psychiatry. LSD from Clinic to Campus, John Hopkins University Press: Baltimore, MA, 2008.
6. D. L. Herzberg. Happy Pills in America: From Miltown to Prozac, Johns Hopkins University Press: Baltimore, MA, 2009.
7. House of Commons Official Report (Hansard), 25 March, cols 1446-560, 1970.
8. House of Commons Official Report (Hansard), 16 July, cols 1749-802, 1970.
9. A. Roberts. Albion Dreaming: A Popular History of LSD in Britain, Marshall Cavendish: London, 2008.
10. J. Stevens. Storming Heaven. LSD and the American Dream, Grove Press: New York, NY, 1998.
11. A. Hoffman. LSD: My Problem Child. Reflections on Sacred Drugs, Mysticism and Science, Multidisciplinary Association for Psychedelic Studies, Sarasota, FL, 2005.
12. M. J. Stolaroff. Thanatos to Eros. 35 Years of Psychedelic Exploration, VWB: Berlin, 1994.
13. European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2010. The State of the Drugs Problem in Europe, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, 2011.
14. R. W. Freudenmann, F. Öxler, S. Bernschneider-Reif. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction 2006, 101, 1241.
15. U. Benzenhöfer, T. Passie. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 2010, 105, 1355.
16. T. R. Gaston, G. T. Rasmussen. Identification of 3, 4-methylene dioxymethamphetamine, Bur. Narc. Danger. Drugs. 1972, 38, 60.
17. M. C. Mithoefer, M. T. Wagner, A. T. Mithoefer, I. Jerome, R. DoblThe safety and efficacy of ± 3, 4-methylenedioxymethampheta mine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J. Psychopharmacol. 2011, 25, 439.
18. J. Holland. Ecstasy: The Complete Guide, Park Street Press: Vermont, 2001.
19. World Health Organization. Lexicon of Alcohol and Drug Terms, World Health Organization: Geneva, 1994.
20. UN. Single Convention on Narcotic Drugs, 1961, (As Amended by the 1972 Protocol Amending the Single Convention on Narcotic Drugs, 1961), United Nations: New York, NY, 1961.
21. UN. Convention on Psychotropic Substances, 1971, United Nations: New York, NY, 1971.
22. J. Saem de Burnaga y Sanchez. Sur un homologue de l'éphédrine. Bull. Soc. Chim. Fr. 1929, 45, 284.
23. F. Schifano, A. Albanese, S. Fergus, J. L. Stair, P. Deluca, O. Corazza, Z. Davey, J. Corkery, H. Siemann, N. Scherbaum, M. Farre, M, Torrens, Z. Demetrovics, A. H. Ghodse. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological, and clinical issues. Psychopharmacology 2011, 214, 593.
24. M. Osorio-Olivares, M. Caroli Rezende, S. Sepúlveda-Boza, B. K. Casselc, R. F. Baggio, J. C. Muñoz-Acevedo. Tetrahedron: Asymmetry 2003, 14, 1473.
25. A. Shulgin, A. ShulgPIHKAL: A Chemical Love Story, Transform Press: Berkley, CA, 1991.
26. A. Shulgin, A. ShulgTIHKAL: The Continuation, Transform Press: Berkley, CA, 1997.
27. G. Shih. 'Godfather' of ecstasy recovers from a stroke, Bay Area Citizen, December 10, 2010.
28. E. M. Rogers. Diffusion of Innovations, Free Press: New York, NY, 2003.
29. J. F. Engel, R. J. Kegerreis, R. D. Blackwell. Word-of-mouth communication by the innovator. J. Marketing 1969, 33, 15.
30. L. F. Monaghan. Vocabularies of motive for illicit steroid use among bodybuilder. Soc. Sci. Med. 2002, 55, 695.
31. C. Lloyd. Sinning and Sinned Against: The Stigmatisation of Problem Drug Users, UK Drug Policy Commission: London, 2010.
32. H. R. Sumnall, F. Measham, S. D. Brandt, J. C. Cole. Salvia divinorum use and phenomenology: results from an online survey. J. Psychopharmacol. 2010, DOI: 10.1177/0269881110385596.
33. A. Gamma, L. Jerome, M. E. Liechti, H. R. Sumnall. Is ecstasy perceived to be safe? A critical survey. Drug Alcohol Depend. 2005, 77, 185.
34. P. I. Dargan, S. Albert, D. M. Wood. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. Q.J.M. 2010, 103, 875.
35. J. Ramsey, P. I. Dargan, M. Smyllie, S. Davies, J. Button, D. W. Holt, D. M. Wood. Buying 'legal' recreational drugs does not mean that you are not breaking the law. Q.J.M. 2010, 103, 777.
36. M. Claire Van Hout, R. Brennan. Plant food for thought: a qualitative study of mephedrone use in Ireland. Drugs Educ. Prev. Policy. 2011, DOI:10.3109/09687637.2010.537713.
37. C. Cole, L. Jones, J. McVeigh, A. Kicman, Q. Syed, M. Bellis. Adulterants in illicit drugs: a review of empirical evidence. Drug Test. Analysis 2010, 3, 89.
38. V. SoodLegal drug teen ripped his scrotum off. The Sun, 26 November, 2009.
39. A. Winstock, J. Ramsey. Legal highs and the challenges for policy makers. Addiction 2010, 105, 1685.
40. L. Monaghan. Challenging medicine? Bodybuilding, drugs and risk. Sociology of Health and Illness 1999, 21, 707.
41. S. Lenton, A. Boys, K. Norcross. Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. Addiction 1997, 92, 1327.
42. E. Finch, L. Sell, D. Arnold. Drug workers emphasise that water is not an antidote to drug. B.M.J. 1996, 313, 690.
43. D. McBarnet, C. Whelan. Creative Accounting and the Cross-Eyed Javelin Thrower, John Wiley and Sons Ltd: Chichester, UK, 1999.
44. M. Evans-Brown, M. A. Bellis, J. McVeigh. Should 'legal highs' be regulated as medicinal products? B.M.J. 2011, 342, d1101.
45. R. P. Archer. Fluoromethcathinone, a new substance of abuse. Forensic Sci. Int. 2009, 185, 10.
46. D. Nutbeam. Health literacy as a public health goal: a challenge for contemporary health education and community strategies in the 21st Century, Health Promot. Int. 2001, 15, 183.
47. N. Bayam. Personal Connections in the Digital Age, Polity Press: Cambridge, UK, 2010.
48. Kaiser Family Foundation. Generation Rx.com: How Young People Use the Internet for Health Information, Henry Kaiser Foundation, Menlo Park, California, 2001.
49. M. Ito, S. Baumer, M. Bittanti, D. Boyd, R. Cody, B. Herr-Stephenson, H. A. Horst, P. G. Lange, D. Mahendran, K. Z. Martínez, C. J. Pascoe, D. Perkel, L. Robinson, C. Sims, L. Tripp. Hanging Out, Messing Around, and Geeking Out: Kids Living and Learning with New Media, MIT Press: London, 2010.
50. R. S. Falck, R. G. Carlson, J. Wang, H. A. Siegal. Sources of information about MDMA (3, 4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users. Drug Alcohol Depend. 2004, 74, 45.
51. P. Deluca, F. Schifano, Psychonaut Research Group. Searching the Internet for drug-related web sites: analysis of online available information on ecstasy (MDMA). Am. J. Addict. 2007, 16, 479.
52. E. W. Boyer, M. Shannon, P. L. Hibberd. Web Sites with misinformation about illicit drugs. N. Eng. J. Med. 2001, 345, 469.
53. J. H. Halpern, H. G. Pope. Hallucinogens on the Internet: a vast new source of underground drug information. Am. J. Psychiatry. 2001, 158, 481.
54. M. Ghoshal, M. F. Walji. Quality of medication information available on retail pharmacy Web sites. Res. Social Adm. Pharm. 2006, 2, 479.
55. E. R. Holmes, S. P. Desselle, D. M. Nath, J. J. Markuss. Ask the pharmacist: an analysis of online drug information services. Ann. Pharmacother. 2005, 39, 662.
56. M. M. Schmidt, A. Sharma, F. Schifano, C. Feinmann. Legal highs on the net-evaluation of UK-based websites, products and product information. Forensic Sci. Int. 2010, 206, 92.
57. S. D. Brandt, H. R. Sumnall, F. Measham, J. C. Cole. The confusing case of NRG-1. B.M.J. 2010, 341, c3564.
58. Anonymous. Available at: [17 May 2011].
59. M. Evans-Brown, R. T. Dawson, M. Chandler, J. McVeigh. Use of melanotan I and II in the general population. B.M.J. 2009, 338, b566.
60. M. Evans-Brown, J. McVeigh, in Elite Sport, Doping and Public Health. (Eds: V. Møller, P. Dimeo, M. McNamee ), University of Southern Denmark Press: Odense, 2009, pp. 75-97.
61. F. Measham, K. Moore, R. Newcombe, Z. Welch. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition, Drug Alcohol Today 2010, 10, 14.
62. A. R. Winstock, L. R. Mitcheson, P. Deluca, Z. Davey, O. Corazza, F. Schifano. Mephedrone, new kid for the chop? Addiction 2010, 106, 154.
63. Advisory Council on the Misuse of Drugs, Consideration of the Cathinones, Home Office: London, 2010.
64. J. Hoare, D. Moon. Drug Misuse Declared: Findings from the 2009/10 British Crime Survey: England and Wales, Home Office: London, 2010.
65. S. Tipping, D. Hussey, M. Wood, J. Hales. British Crime Survey: Methods Review 2009. Final Report, Home Office: London, 2010.
66. Council of the European Union. Council decision 2005/387/JHA. Off. J. Eur. Union 2005, 48, 32.
67. European Monitoring Centre for Drugs and Drug Addiction. Early-Warning System on New Psychoactive Substances. Operating Guidelines, Publications Office of the European Union, Luxembourg, 2007.
68. T. Babor, J. Caulkins, G. Edwards, B. Fischer, D. Foxcroft, K. Humphreys, I. Obot, J. Rehm, P. Reuter, R. Room, I. Rossow, J. Strang. Drug Policy and the Public Good, Oxford University Press: Oxford, UK, 2010.
69. European Monitoring Centre for Drugs and Drug Addiction. Risk Assessment of New Psychoactive Substances. Operating Guidelines, Publications Office of the European Union: Luxembourg, 2010.
70. Consumer Protection (Distance Selling) Regulations 2000. Available at: [5 June 2011].
71. Independent Drug Monitoring Unit. Available at: [10 May 2011].
72. H. R. Sumnall, E. Tyler, G. F. Wagstaff, J. C. Cole. A behavioural economic analysis of alcohol, amphetamine, cocaine, and ecstasy purchases by recreational polydrug users. Drug Alcohol Depend. 2004, 76, 93.
73. European Monitoring Centre for Drugs and Drug Addiction, Europol-EMCDDA. Joint Report on a new psychoactive substance: 4-methylmethcathinone (mephedrone), European Monitoring Centre for Drugs and Drug Addiction: Lisbon, 2010.
74. European Monitoring Centre for Drugs and Drug Addiction. Report on the Risk Assessment of Mephedrone in the Framework of the Council Decision on New Psychoactive Substances, Publications Office of the European Union: Luxembourg, 2011.
75. M. Evans-Brown, A. Kimergard, J. McVeigh. Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market. Drug Test. Analysis 2009, 1, 323.
76. P. N. Newton, F. M. Fernandez, A. Plancon, D. C. Mildenhall, M. D. Green, L. Ziyong, E. M. Christophel, S. Phanouvong, S. Howells, E. McIntosh, P. Laurin, N. Blum, C. Y. Hampton, K. Faure, L. Nyadong, C.W.R. Soong, B. Santoso, W. Zhiguang, J. Newton, K. Palmer. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med. 2008, 5, e32.
77. K. McElrath, C. O'Neill. Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int. J. Drug Policy 2011, 22, 120.
78. A. R. Winstock, L. Mitcheson, J. Ramsey. Mephedrone: still available and twice the price. Lancet 2010, 376, 1537.
79. S. Bird, Banned drug may have saved lives, not cost them. Available at: [14 February 2011].
80. J. Butcher. Sacked drugs adviser David Nutt speaks out. The Journal, 4 February 2011.
81. S. S. Nagel. Policy Analysis Methods, Nova Science Publishers, Inc: Commack, NY, 1999.
82. A. H. Ghodse, J. Corkery, A. Oyefeso, F. Schifano, K. Ahmed, V. Naidoo. Drug related deaths in the UK. Annual Report 2010, International Centre for Drug Policy, St George's University of London: London, 2010.
83. J. Talbot, P. Waller. Stephens' Detection of New Adverse Drug Reactions, John Wiley & Sons Ltd: Chichester, UK, 2007.
84. B. L. Strom. Pharmacoepidemiology, John Wiley & Sons Ltd: Chichester, UK, 2005.
85. R. Mann, E. Andrews. Pharmacovigilance, John Wiley & Sons Ltd: Chichester, UK, 2007.
86. Association of Chief Police Officers of England Wales and Northern Ireland, in Guidance on Policing New Psychoactive Substances (Formerly Legal Highs), Association of Chief Police Officers of England: Wales and Northern Ireland, London, 2010, pp. 8.
87. R. Fortson, in Misuse of Drugs: Offences, Confiscation and Money Laundering, Sweet & Maxwell: London, 2005, pp. 4-7.
88. Independent Inquiry into the Misuse of Drugs Act 1971. Drugs and the Law. Report of the Independent Inquiry into the Misuse of Drugs Act 1971, Police Foundation, London, 2000.
89. M. Tiggey, H. Warburton, P. J. Turnbull, M. Hough. Times They Are A-Changing: Policing of Cannabis, Joseph Rowntree Foundation: York, UK, 2002.
90. M. Lee, N. South, in Handbook of Policing. (Ed: T. Newburn ), Willan Publishing: Cullompton, 2008, pp. 507-509.
91. Misuse of Drugs Act 1971, 1971.Available at: [5 June 2011].
92. R. Fortson, in Misuse of Drugs: Offences, Confiscation and Money Laundering, Sweet & Maxwell: London, 2005, pp. 183.
93. R. Fortson, in Misuse of Drugs: Offences, Confiscation and Money Laundering, Sweet & Maxwell: London, 2005, pp. 311.
94. R. L. Carhart-Harris, L. A. King, D. J. Nutt. A web-based survey on mephedrone. Drug Alcohol Depend 2011, 10, 1016.
95. L. Donohew, R. Zimmerman, P. S. Cuppa, S. Novak, S. Colon, R. Abell. Sensation seeking, impulsive decision-making, and risky sex: implications for risk-taking and design of interventions. Pers. Individ. Dif. 2000, 6, 1079.
96. Anonymous. The 2011 Drug Survey, Mixmag, March 2011, pp. 49.
97. D. J. Nutt, L. A. King, L. D. Phillips. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010, 376, 1558.
98. A. Ritter. How do drug policy makers access research evidence? Int. J. Drug Policy 2009, 20, 70.
99. M. Monaghan. Evidence Versus Politics: Exploiting Research in UK Drug Making Policy? Policy Press: Bristol, UK, 2011.
100. L. A. King, in Forensic Chemistry of Substance Misuse: A Guide to Drug Control, Royal Society of Chemistry: London, 2010, pp. 123.
101. B. Hughes, T. Blidaru. Legal Responses to New Psychoactive Substances in Europe, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, 2009.
102. R. Kikura-Hanajiri, N. Uchiyama, Y. Goda. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Legal Med. 2011, 13, 109.
103. Law Commission. Controlling and Regulating Drugs. A Review of the Misuse of Drugs Act 1975, Law Commission: Wellington, New Zealand 2011.
104. J. Birdwell, J. Chapman, N. Singleton. Taking drugs seriously. A Demos and UK Drug Policy Commission report on legal highs, Demos, London, 2011.
105. S. Van Evera, in Perspectives on Structural Realism. (Eds: A. K. Hanami ), Palgrave Macmillan: Basingstoke, UK, 2003, pp. 163.
106. S. D. Brandt, R. C. Wootton, G. De Paoli, S. Freeman. The naphyrone story: The alpha or beta-naphthyl isomer? Drug Test. Analysis 2010, 2, 496.
107. P. C. Meltzer, D. Butler, J. R. Deschamps, B. K. Madras. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49, 1420.
108. A. P. Monte, D. Marona-Lewicka, N. V. Cozzi, D. E. Nichols. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3, 4-methylenedioxyamphetamine. J. Med. Chem. 1993, 36, 3700.
109. European Monitoring Centre for Drugs and Drug Addiction. Risk Assessment of New Psychoactive Substances. Operating Guidelines, Publications Office of the European Union: Luxembourg, 2010.
110. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2010 Annual Report on the Implementation of Council Decision 2005/387/JHA, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, 2011.
111. Psychonaut Web Mapping Research Group. Psychonaut Web Mapping Project: final report, Institute of Psychiatry, King's College London: London, 2010.
112. D. Nichols. Legal highs: the dark side of medicinal chemistry. Nature 2011, 469, 7.
113. D. E. Nichols, W. K. Brewster, M. P. Johnson. Nonneurotoxic tetralin and indan analogues of 3, 4-(methylenedioxy)amphetamine (MDA). J. Med. Chem. 1990, 33, 703.
114. E. E. Tanner-Smith. Pharmacological content of tablets sold as 'ecstasy': results from an online testing service. Drug Alcohol Depend. 2006, 83, 247.
115. M. G. Bossong, T. M. Brunt, J. P. Van Dijk, S. M. Rigter, J. Hoek, H. M. Goldschmidt, R. J. Niesink. mCPP: an undesired addition to the ecstasy market. J. Psychopharmacol. 2010, 24, 1395.
116. M. E. Tancer, C. E. Johanson. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2001, 65, 97.
117. J. Ott. Pharmacotheon, Natural Products Company, Kennewick, WA, 1993.
118. A. Shulgin, W. E. Perry. The Simple Plant Isoquinolines, Transform Press: Berkley, CA, 2002.
119. A. ShulgThe Shulgin Index Volume 1, Psychedelic Phenethylamines and Related Compounds, Transform Press: Berkley, CA, 2011.
120. L. King, A. Kicman, DTA Editorial, Drug Test Analysis. 2011, [this issue-to be completed by production when issue has been paginated].
121. J. C. Cole, A. J. Goudie, M. Field, A. C. Loverseed, S. Charlton, H. R. Sumnall. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug Alcohol Depend. 2008, 94, 183.
122. J. van der Pligt. Risk perception and self-protective behaviour. Eur. Psychol. 1996, 1, 34.
123. X. M. Huang, D. Marona-Lewicka, D. E. Nichols. p-Methylthioam phetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol. 1992, 229, 31.
124. European Monitoring Centre for Drugs and Drug Addiction. Report on the Risk Assessment of 4-MTA in the Framework of the Joint Action on New Synthetic Drugs, European Monitoring Centre for Drugs and Drug Addiction: Lisbon, 1999.
125. Police Reform and Social Responsibility Bill, HL Bill 62, 2011.
126. The Misuse of Drugs Regulations 2001, 2001, Available at: [5 June 2011].
127. T. Rhodes. Risk environments and drug harms: A social science for harm reduction approach. Int. J. Drug Policy 2009, 20, 193.
128. K. J. Lusthof, R. Oosting, A. Maes, M. Verschraagen, A. Dijkhuuizen, A. G. Sprong. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci. Int. 2011, 206, e93.
129. D. Gustavsson, C. Esher. Mefedron-Internetdrog som tycks ha kommit för att stanna Dö dsfall i Sverige fä ste uppmä rksamheten pä tidigare okänd substans, Lakartidningen 2009, 106, 2769.